March 21, 2022
Article
“The question of who is a candidate for active surveillance is hard to answer because this is a bedside, gut decision," says Primo Nery Lara, Jr, MD.
February 18, 2022
Article
“Darolutamide improved overall survival despite a high rate of subsequent life prolonging systemic therapies in the placebo group,” said Matthew R. Smith, MD, PhD, lead author of the phase 3 ARASENS trial.
October 28, 2021
Article
“Patients with intermediate-risk prostate cancer we know benefit from both escalation of radiotherapy dose as well as from the addition of androgen suppression. Technically, we still don’t know if we need both,” said Daniel Krauss, MD.
September 17, 2021
Article
Episodic memory by computerized cognitive assessment was significantly improved in patients who received darolutamide compared with those treated with enzalutamide.